FDA lifts hold from Aastrom's Phase II study of cardiac repair cells
This article was originally published in Scrip
Executive Summary
The US FDA has lifted its clinical hold on Aastrom's Phase II IMPACT-DCM trial evaluating cardiac repair cells (CRCs) for the treatment of dilated cardiomyopathy (DCM), which was imposed after a patient died in May (scripnews.com, May 28th, 2009).